Northland Securities Predicts Indivior Q1 Earnings

Indivior PLC (NASDAQ:INDV) – Equities research analysts at Northland Securities issued their Q1 2026 earnings estimates for shares of Indivior in a note issued to investors on Tuesday, January 20th. Northland Securities analyst C. Byrnes expects that the company will earn $0.61 per share for the quarter. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. Northland Securities also issued estimates for Indivior’s Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.10 EPS.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The business had revenue of $314.00 million for the quarter, compared to analysts’ expectations of $257.66 million.

A number of other brokerages also recently commented on INDV. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 target price (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. Craig Hallum reiterated a “buy” rating and set a $41.00 target price on shares of Indivior in a research note on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Finally, Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.00.

Indivior Stock Up 0.1%

Indivior stock opened at $32.98 on Wednesday. Indivior has a 52 week low of $7.62 and a 52 week high of $38.00. The company’s 50 day moving average price is $34.47 and its two-hundred day moving average price is $26.99. The stock has a market cap of $4.12 billion, a P/E ratio of 35.85 and a beta of 0.75.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently modified their holdings of the business. Harbor Capital Advisors Inc. boosted its holdings in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the period. CWM LLC purchased a new stake in shares of Indivior during the third quarter worth $25,000. Quarry LP purchased a new stake in shares of Indivior during the third quarter worth $26,000. GAMMA Investing LLC boosted its holdings in shares of Indivior by 544.6% in the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Indivior in the second quarter valued at $26,000. Institutional investors own 60.33% of the company’s stock.

Insider Activity

In other news, Director Barbara Ryan acquired 775 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. The trade was a 65.24% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David E. Wheadon acquired 1,771 shares of the company’s stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares of the company’s stock, valued at approximately $509,439.05. The trade was a 14.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 4,871 shares of company stock worth $172,385.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.